CIBC Asset Management
RXRX icon

CIBC Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

CIBC Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.2K Hold
15,865
– – ﹤0.01% 1402
2026
Q1 		$48.7K Hold
15,865
– – ﹤0.01% 1348
2025
Q4 		$64.9K Buy
+15,865
New +$78.6K ﹤0.01% 1329

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

CIBC Asset Management's RXRX Position: Q2 2026 in Review

CIBC Asset Management held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 15,865 shares worth $58.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1402.

CIBC Asset Management first reported a position in RXRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $64.9K in Q4 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • CIBC Asset Management held 15,865 shares of Recursion Pharmaceuticals worth $58.2K as of Q2 2026.
  • CIBC Asset Management left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of CIBC Asset Management's portfolio in Q2 2026, its #1402 holding.
  • CIBC Asset Management first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • CIBC Asset Management's Recursion Pharmaceuticals position peaked at $64.9K in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.